Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
BrightStar-2 trial: what clinicians have said so far
Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
- NCT06522360 ↗
- Withdrawn
- M.D. Anderson Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on BrightStar-2 (brigatinib plus carboplatin plus pemetrexed; brigatinib in ALK-positive advanced non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BrightStar-2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)
- Phase
- Phase 2
- Status
- Withdrawn
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Brigatinib; Carboplatin; Pemetrexed
- Arms
- Brigatinib Monotherapy · Experimental
- Brigatinib + Carboplatin + Pemetrexed · Experimental
- Brigatinib + Local Consolidation Therapy (LCT) · Experimental
- Enrollment
- 0
- Primary outcomes
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
- Sponsor
- M.D. Anderson Cancer Center
- Start
- Dec 11, 2024
- Primary completion
- Apr 17, 2025
- Results posted
- No
- Registry record
- NCT06522360 · updated Apr 24, 2025